Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

BACKGROUND: High-dose interferon alfa-2b (IFNalfa-2b), according to the ECOG 1684 schedule, is the only approved adjuvant treatment for stage III melanoma patients by the FDA and EMEA. However, the risk/benefit profile has been questioned limiting its world-wide use. In the late nineties, the Italia...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiarion-Sileni, Vanna, Del Bianco, Paola, Romanini, Antonella, Guida, Michele, Paccagnella, Adriano, Dalla Palma, Maurizio, Naglieri, Emanuele, Ridolfi, Ruggero, Silvestri, Barbara, Michiara, Maria, De Salvo, Gian Luca
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1421423/
https://www.ncbi.nlm.nih.gov/pubmed/16504154
http://dx.doi.org/10.1186/1471-2407-6-44

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1421423/
https://www.ncbi.nlm.nih.gov/pubmed/16504154
http://dx.doi.org/10.1186/1471-2407-6-44

Ejemplares similares